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Abstract
The hypothesis that human cancers express antigens that can be specifically targeted by cell
mediated immunity has become a scientifically justifiable rationale for the design and clinical testing
of novel tumor-associated antigens (TAA). Although a number of TAA have been recognized and
it has been suggested that they could be useful in the immunological treatment of cancer, the
complexity of human beings leads us to reflect on the need to establish new criteria for validating
their real applicability. Herein, we show a system level-based approach that includes morphological
and molecular techniques, which is specifically required to improve the capacity to produce desired
results and to allow cancer immunotherapy to re-emerge from the mist in which it is currently
shrouded.
Introduction
Although considerable advances have been made in terms
of our molecular and cellular knowledge, for most human
disease states a fundamental understanding of causal dis-
ease onset, disease mechanism and progression, and opti-
mal treatment is still significantly limited.
In part, this advancement has been hampered by our ina-
bility to fully and rapidly delineate complex cellular met-
abolic processes and molecular pathways.
Organisms are complex self-organizing entities made up
of such parts: organs, tissues, cells, organelles and ulti-
mately molecules and atoms. One question that arises,
concerns the relationship between the whole and its com-
ponent parts. The issue at stake is sometimes called "the
question of reduction" or "the problem of reductionism"
[1].
The inefficacy of contemporary science to describe biolog-
ical systems, consisting of non-identical parts that have
different and non-local interactions has tended to limit
progress in the human healthcare. Many biological sys-
tems remain incomprehensible because their multifarious
nature has been combined with a reductionist approach
based on the linear conception of cause and effect.
The use, however, of a more holistic multidimensional sys-
tem level-based approach may provide new insights into
the understanding of disease processes and mechanisms
of action of therapeutical agents [2].
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Herein we aim to introduce a system level-based approach
that includes morphological and molecular techniques
for validating the appropriateness of using novel tumor-
associated antigens (TAA) for clinical purposes. This
approach might be easily implemented for identifying
prognostic, diagnostic and alternative biomarkers.
Finally, this type of analysis of appropriately designed
cohorts might also provide a key to understanding the dif-
ferences in patients who do or do not respond to any par-
ticular therapy. This information may be helpful for a
more effective (and therefore more cost-effective) design of
clinical trials [2].
Immunotherapy and the human complexity
The recognition and characterization of novel TAA is fun-
damental to the advance of cancer immunotherapy. The
original hypothesis of Boon [3] and Rosenberg [4] that
human cancers express antigens that can be specifically
targeted by cell mediated immunity has become a scientif-
ically justifiable rationale for the design and clinical test-
ing of novel TAA based immunotherapies and therapeutic
vaccines [5-7].
However, although a number of TAA have been discov-
ered and it has been suggested that they could be useful in
the immunological treatment of cancer, the complexity of
human beings leads us to reflect on the need to establish
compelling new criteria for validating their real applica-
bility. Biological complexity can be intuitively appreciated –
at least in terms of morphological or behavioral complex-
ity, or the variety of cell types in an organism – but the
term itself is notoriously difficult to define [8]. Human
beings are complex hierarchical systems consisting of a
number of levels of anatomical organization (genes, cells, tis-
sues, organs, apparatuses, and organism) that interrelate
differently with each other to form networks of growing
complexity. The concept of anatomical entities as hierar-
chy of graduated forms, and the increasing number of
known structural variables, have highlighted new proper-
ties of organized biological matter and raised a series of
intriguing questions. In order to understand biology at the
system level, we need to examine the structure and dynam-
ics of the functions of organisms rather than the character-
istics of their constitutive isolated parts [8-13].
The expression of TAA in biological materials has mainly
been studied at the level of gene expression and gene level
measurement by Reverse Transcriptase-Polymerase Chain
Reaction (RT-PCR) analysis and the Quantitative real-
time PCR (qrt-PCR) technology [14-17]. However, the
information provided by these approaches is limited by the
fact that the phenomena observed at each level of anatom-
ical organization have properties that do not exist at a
lower or higher level: RT-PCR and qrt-PCR may offer a sat-
isfactory qualitative/quantitative description of small-scale
structures, but this is likely to be irrelevant when it comes
to large-scale features. The above considerations, in con-
junction with the complexity of tumor-host interactions
within the tumor microenvironment caused by temporal
changes in tumor phenotypes and an array of immune
mediators expressed in the tumor microenvironment [18]
might clarify the limited reliability and applicability of
current immunotherapeutic approaches.
Here, we suggest a system level-based approach (Figure 1)
for validating the appropriateness of using TAA for clinical
purposes, which includes the following never defined
before key points:
• Discriminating the cell types expressing the candidate anti-
gen on the basis of the morphological visualization of all
of the parts making up the organ under investigation.
• Discriminating the candidate antigen's sub-cellular local-
ization (at the level of cell nucleus, cytoplasm and/or plasma
membrane) by ultra-structural morphological
visualizations.
• Mapping candidate antigen expression in all of the organs
making up the apparatuses.
• Mapping candidate antigen expression in all of the appa-
ratuses making up the living organism.
• Estimating the percentage of normal cells and their neo-
plastic counterparts expressing the candidate antigen.
• Evaluating the dynamics of candidate antigen expression
at the level of the cell cycle, the physiological status of the
organism (i.e. the woman's menstrual cycle) and the process
of aging.
In order to advance our knowledge in a currently widely
debated field of investigation, a clearer distinction must
be made between in vitro laboratory results (the discovery
and validation of target antigens) and their in vivo appli-
cation (in vivo validation), and it is necessary to adopt a
more complete experimental approach that forcefully
includes both morphological and molecular techniques
[19].
Conclusions
Translational science which is aimed to test, in humans,
novel therapeutic strategies developed through experi-
mentation [20] should begin to consider the role of emer-
gence  in other words the appearance of unexpected
structures and/or the occurrence of surprising behaviors in
large systems composed from microscopic parts, whether
physical or biological. By unexpected and surprising weJournal of Translational Medicine 2004, 2:26 http://www.translational-medicine.com/content/2/1/26
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mean structures and behaviors which are not intuitive and
are not simply predictable.
Since our understanding of complex human disease such
as cancer, is still limited and pre-clinical models have
shown a discouraging propensity [2,6] to fail when
applied to humans, a new way of thinking is strongly
needed that unites physicians, biologists, mathematicians
and epidemiologists, in order to develop a better theoret-
ical framework of tumor development, progression and
tumor-host interactions.
Although the model presented here is based on a multi-
disciplinary system-level approach probably within the
reach of only very large and multi-talented laboratories, it
is aimed to introduce a different way of investigating
human cancer, which takes into account the complexity of
the human being as a system.
The use of a holistic approach, which enables a more accu-
rate selection of immunotherapeutic target antigens in the
first phase of the experimental research, will reduce the
notable fragmentation of the biological information in
the post-genomic era, and will facilitate a more accurate
transfer of the acquired knowledge to the bedside.
Further, this new multidisciplinary approach is specifi-
cally required to improve the capacity to produce desired
results with a minimum expenditure of energy, time, or
resources for immunotherapeutic treatments and to allow
cancer immunotherapy to re-emerge from the mist in
which it is currently shrouded.
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